Company Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Hong Kong S.E.
Equities
2196
CNE100001M79
Pharmaceuticals
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.58 HKD | +1.19% |
|
-0.59% | -20.12% |
Business Summary
- research, development and manufacturing of medicines (72.1% of net sales): for the treatment of cardiovascular diseases, digestive tract, metabolism, central nervous system and blood system disorders, and infectious diseases;
- sale of medical equipments and diagnosis products (17.3%);
- medical and hospital services (10.5%);
- other (0.1%).
China accounts for 72.9% of net sales.
Number of employees: 40,370
Sales per Business
CNY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical
73.0
%
| 30,812 | 70.1 % | 30,222 | 73.0 % | -1.91% |
Medical and Health Services
16.1
%
| 6,080 | 13.8 % | 6,672 | 16.1 % | +9.74% |
Medical Devices and Medical Diagnosis
10.6
%
| 6,949 | 15.8 % | 4,390 | 10.6 % | -36.83% |
Other
0.3
%
| 110 | 0.3 % | 115 | 0.3 % | +4.48% |
Sales per region
CNY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
China
74.9
%
| 30,013 | 68.3 % | 31,029 | 74.9 % | +3.38% |
Other Countries or Regions
25.1
%
| 13,938 | 31.7 % | 10,371 | 25.1 % | -25.60% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
De Yong Wen
CEO | Chief Executive Officer | 52 | - |
Shirley Wu
DFI | Director of Finance/CFO | 44 | 16-12-31 |
Dong Ming Li
PSD | President | 55 | 20-10-28 |
Ke Xin Wang
CHM | Chairman | 60 | 20-10-28 |
Yi Fang Wu
CHM | Chairman | 54 | 04-03-31 |
Hequn Yin
CTO | Chief Tech/Sci/R&D Officer | 60 | - |
Qi Yu Chen
BRD | Director/Board Member | 52 | 94-03-31 |
Xing Li Wang
PRN | Corporate Officer/Principal | 61 | - |
Rong Li Feng
PRN | Corporate Officer/Principal | 49 | - |
Ai Min Hui
SAM | Sales & Marketing | 61 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Qi Yu Chen
BRD | Director/Board Member | 52 | 94-03-31 |
Xiao Hui Guan
BRD | Director/Board Member | 53 | - |
Yi Fang Wu
CHM | Chairman | 54 | 04-03-31 |
Xiao Liang Xu
BRD | Director/Board Member | 51 | 19-06-24 |
Ke Xin Wang
CHM | Chairman | 60 | 20-10-28 |
Ling Li
BRD | Director/Board Member | 62 | 19-06-24 |
Dong Hui Pan
BRD | Director/Board Member | 54 | 20-06-29 |
De Yong Wen
CEO | Chief Executive Officer | 52 | - |
Quan Di Wang
BRD | Director/Board Member | 74 | 21-06-10 |
Bing Chen
CHM | Chairman | 50 | 23-06-27 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 551,940,500 | 473,969,000 ( 85.87 %) | 0 | 63.46 % |
Stock B | 1 | 2,120,458,211 | 1,222,025,582 ( 57.63 %) | 1,969,386 ( 0.0929 %) |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
GLAND PHARMA LIMITED 51.83% | 85,393,894 | 51.83% | 1,868,399,614 $ |
SISRAM MEDICAL LTD 71.42% | 334,504,800 | 71.42% | 154,240,163 $ |
32,331,100 | 19.78% | 94,623,754 $ | |
YSB INC. 7.60% | 48,721,760 | 7.60% | 50,235,545 $ |
17,186,726 | 0.99% | 11,519,231 $ |
Company contact information
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Building A No. 1289 Yishan Road
200233, Shanghai
+86 21 3398 7000
http://www.fosunpharma.com![address Shanghai Fosun Pharmaceutical (Group) Co., Ltd.(2196)](https://cdn.zonebourse.com/static/address/11813653.png)
Group companies
Name | Category and Sector |
---|---|
Chindex Hong Kong Ltd.
|
Sector
Sales per Business
Sales per region
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+60.25% | 841B | |
+38.99% | 625B | |
-4.49% | 360B | |
+18.30% | 327B | |
+9.64% | 300B | |
+15.49% | 242B | |
+4.13% | 228B | |
+18.46% | 227B | |
+12.87% | 174B |
- Stock Market
- Equities
- 600196 Stock
- 2196 Stock
- Company Shanghai Fosun Pharmaceutical (Group) Co., Ltd.